TMEFF2抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P12303(TMEFF2 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

TMEFF2 (transmembrane protein with EGF-like and two follistatin-like domains 2), also known as tomoregulin-2. is a single-pass transmembrane protein characterized by an extracellular region containing EGF-like and follistatin-like domains. It is primarily expressed in the brain and prostate, with roles in cell signaling, adhesion, and differentiation. TMEFF2 has garnered attention due to its dual role in cancer biology, acting as either a tumor suppressor or oncogene depending on context. In prostate cancer, TMEFF2 is frequently downregulated, and its loss correlates with disease progression. Conversely, in glioblastoma and other brain malignancies, TMEFF2 overexpression has been linked to tumor growth and poor prognosis. This context-dependent behavior makes it a complex therapeutic target.

Antibodies targeting TMEFF2 are valuable tools for studying its expression patterns, localization, and interaction partners. They enable detection via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Commercially available antibodies often recognize specific epitopes in its extracellular or intracellular domains. In research, these antibodies help investigate TMEFF2's involvement in pathways such as BMP (bone morphogenetic protein) signaling and receptor tyrosine kinase modulation. Clinically, TMEFF2 antibodies are explored for diagnostic applications (e.g., distinguishing cancer subtypes) and therapeutic development, including antibody-drug conjugates. However, challenges remain in optimizing specificity and validating cross-reactivity across species and isoforms.